רווח תפעולי לפני פחת: celcuity.com (CELC)

Celcuity Inc. is developing a biotech environment for live tumor analysis, integrating the CELx platform into the developments of major pharmaceutical companies. The absolute operating profit figure demonstrates the market reaction, where 0.00 shows the level of this metric. Revenues are based on providing clinics with data on cancer cell functionality. However, the commercial launch and patient inflow await final FDA approval.

Celcuity Inc. (CELC) requires significant resources to maintain its technological edge through a personalized approach to cancer therapy via cellular analysis. This EBITDA chart captures daily cash flow from core operations minus non-cash expenses, allowing investors to strip away accounting adjustments and assess the real operational resilience of the business, which is critical for determining the asset's long-term investment attractiveness.